A Study to Evaluate the Intramuscular Administration of Scopolamine
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04314713 |
Recruitment Status :
Terminated
(DSMB decision due to adverse events)
First Posted : March 19, 2020
Last Update Posted : June 3, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Scopolamine Causing Adverse Effects in Therapeutic Use | Drug: Scopolamine Hydrobromide Trihydrate | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Masking Description: | double-blinded, randomized, placebo-controlled |
Primary Purpose: | Prevention |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study To Evaluated The Safety, Tolerability, and Pharmacokinetics Of Intramuscular Administration Of Scopolamine Hydrobromide Trihydrate, Injection |
Actual Study Start Date : | June 2, 2020 |
Actual Primary Completion Date : | April 6, 2021 |
Actual Study Completion Date : | May 6, 2021 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Scopolamine HBT 0.005 mg/kg
Dose of Scopolamine 0.005mg/kg verses Placebo
|
Drug: Scopolamine Hydrobromide Trihydrate
Scopolamine Hydrobromide Trihydrate Intramuscular Injection |
Placebo Comparator: Scopolamine HBT 0.007 mg/kg
Dose of Scopolamine 0.007mg/kg verses Placebo
|
Drug: Scopolamine Hydrobromide Trihydrate
Scopolamine Hydrobromide Trihydrate Intramuscular Injection |
Placebo Comparator: Scopolamine HBT 0.011 mg/kg
Dose of Scopolamine 0.011mg/kg verses Placebo
|
Drug: Scopolamine Hydrobromide Trihydrate
Scopolamine Hydrobromide Trihydrate Intramuscular Injection |
Placebo Comparator: Scopolamine HBT 0.014 mg/kg
Dose of Scopolamine 0.014mg/kg verses Placebo
|
Drug: Scopolamine Hydrobromide Trihydrate
Scopolamine Hydrobromide Trihydrate Intramuscular Injection |
Placebo Comparator: Scopolamine HBT 0.021 mg/kg
Dose of Scopolamine 0.021mg/kg verses Placebo
|
Drug: Scopolamine Hydrobromide Trihydrate
Scopolamine Hydrobromide Trihydrate Intramuscular Injection |
No Intervention: Placebo
Placebo controlled
|
- Determine degree and number of adverse events experienced by subjects. [ Time Frame: 30 Days (+7) ]To characterize the safety and tolerability profile of ascending doses of scopolamine hydrobromide trihydrate (Scopolamine HBT) administered by intramuscular (IM) injection
- Determine what the what the body does with the movement of drug within the body of Scopolamine HBT after IM Administration. [ Time Frame: 30 Days (+7) ]A goal of this clinical study is to measure Scopolamine HBT immunity remaining in each participant after IM administration. The predicted efficacious Cmax, based on limited nonclinical studies, is 16-18 ng/mL. At the end of each cohort, the PI, DSMB, and sponsor will evaluate the safety outcomes and PK data associated with the Scopolamine HBT dosing for that group.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male or female, 18 to 55 years of age, inclusive, at the time of drug administration
- Without clinically significant abnormities on physical examination at screening or prior to drug administration
- Generally healthy, as determined by medical history review, physical examination, and laboratory testing at screening and prior to drug administration
- Must have a BMI (body mass index) of ≥ 19.0 and ≤ 30.0, and weight range of 55.0 to 85.0 kg at screening or prior to drug administration
- Must have adequate venous access and sufficient upper leg muscle tissue for drug administration
- If female, the subject must be nonpregnant and nonbreastfeeding, and have a negative serum pregnancy test at screening and prior to drug administration
- If female of childbearing potential, the subject must have been using adequate contraception (as defined in Section 5.3.1.5) for at least 3 months prior to drug administration and must agree to use an adequate method of contraception for at least 30 days following drug administration
- Females of nonchildbearing potential are also eligible, defined as a subject who is postmenopausal (continuous amenorrhea for 24 months) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or total hysterectomy)
- A male with a female partner of childbearing potential must agree to use a barrier method of contraception (defined as condoms with spermicide) for at least 30 days following drug administration
- If male, must not have past diagnoses of benign prostatic hypertrophy or urinary tract obstruction and must not have on screening history/review of systems symptoms suggestive of urinary tract obstruction (eg, urinary hesitancy, urgency, frequency, or nocturia)
- Nonsmoker/tobacco/nicotine product (including e-cigarettes) user within 3 months of first dosing and must have a total lifetime exposure to cigarettes of < 15 pack-years
- No evidence of significant neuropsychiatric disorders based on the Brief Psychiatric Rating Scale (BPRS) at screening and prior to drug administration, which is defined as having a global score of ≤ 25 with no score higher than 2 on any one item, with the exception of a score of 1 (ie, Not Present) to disorientation, hallucinatory behavior, and suspiciousness (ie, paranoia)
- No evidence of suicidal ideation or behavior at screening and prior to drug administration, which is defined as having a global score of 0 on the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Ability to read, speak, and comprehend English and a willingness to sign informed consent
Exclusion Criteria:
- Received any other investigational drug within 30 days prior to drug administration
- Known allergies to any component of the study drug, other belladonna alkaloids, or the recovery medications (physostigmine, atropine, or benzodiazepines [diazepam or lorazepam])
- History of migraine headaches or seizures
- History of psychosis or psychotic episodes
- Clinically relevant abnormal physical findings (including vital signs) as determined by the investigator at screening or prior to drug administration that could interfere with the objectives of the study or the safety of the subject
- Has ongoing drug abuse/dependence (including alcohol), recent history (over the past 5 years) of treatment for alcohol or drug abuse, or a current positive alcohol breathalyzer test or current positive urine test for drugs of abuse (as defined in Section 11.1.9.5) at screening or prior to drug administration
- Has consumed Seville orange (bitter orange), grapefruit, grapefruit juice, other grapefruit-containing products, or starfruit within 7 days prior to dosing
- Has consumed caffeine or other xanthine-containing products within 7 days prior to dosing
- Has any specified laboratory values (eg, hematology, serum chemistry, and urinalysis) outside of the normal range for age and sex and deemed clinically significant by the investigator within 30 days before drug administration
- Has positive (reactive) test results for hepatitis B surface antigen, hepatitis C, syphilis, HIV-1, or HIV-2
- Has narrow-angle glaucoma or high intraocular pressures in either or both eyes
- Has pyloric obstruction or urinary bladder neck obstruction
- Has impaired liver or kidney functions
- Clinically relevant electrocardiogram (ECG) abnormalities on any 12-lead ECG obtained at screening or prior to dosing
- ECG with a PR interval ≥ 200 msec at screening or prior to dosing
- ECG with QRS duration > 120 msec at screening or prior to dosing
- ECG RR interval > 1500 msec at screening or prior to dosing
- ECG with a QTc interval > 450 msec for males or 470 msec for females (QT interval corrected with Fridericia correction [QTcF]) at screening or prior to dosing
- Systolic blood pressure > 140 mm Hg and/or diastolic blood pressure > 90 mm Hg at screening or prior to dosing
- Systolic blood pressure < 90 mm Hg and/or diastolic blood pressure < 50 mm Hg at screening or prior to dosing
- Currently taking or has taken other antimuscarinic drugs such as phenothiazines, tricyclic antidepressants, antihistamines (including meclizine), meperidine, or other anticholinergics that have weak antimuscarinic activity or that cause drowsiness, including antidepressants, benzodiazepines, alcohol, sedatives (used to treat insomnia), pain relievers, anxiety medicines, and muscle relaxants within 72 hours prior to dosing
- Has taken, within 14 days of planned dosing, any prescription or nonprescription medication (including home remedies, herbal supplements, or nutritional supplements) unless the PI/subinvestigator, in consultation with the medical monitor, provides a statement justifying that the medication taken will not impact the results of this study (with rare exceptions taking prescriptions drugs will be grounds for exclusion)
- History of major DSM-5 Axis I or II disorder, or evidence of such disorder at Day -1 as determined via the Structured Clinical Interview for DSM-5, customized Clinical Trials version (SCID-5-CT)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04314713
United States, Maryland | |
Pharmaron | |
Baltimore, Maryland, United States, 21201 |
Responsible Party: | Battelle Memorial Institute |
ClinicalTrials.gov Identifier: | NCT04314713 |
Other Study ID Numbers: |
S-16-14 |
First Posted: | March 19, 2020 Key Record Dates |
Last Update Posted: | June 3, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Scopolamine |
Scopolamine Butylscopolammonium Bromide Adjuvants, Anesthesia Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents |
Mydriatics Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Muscarinic Antagonists Parasympatholytics |